Cytokinetics, Incorporated (NASDAQ: CYTK) reported total revenues of $8.0 million for the first quarter of 2014, compared to $0.8 million during the same period in 2013. Net loss for the first quarter of 2014 was $8.7 million or $0.27 per basic share and diluted share. This is compared to a net loss for the same period in 2013, of $12.6 million, or $0.53 per basic and diluted share. Cytokinetics, Inc. (NASDAQ:CYTK) weekly performance is -13.02%. On last trading day company shares ended up $4.01. Analysts mean target price for the company is $11.86. Cytokinetics, Inc. (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is -54.93%.
ImmunoGen Inc. (NASDAQ:IMGN) reported third quarter fiscal 2014 (ending Mar 31, 2014) loss of 29 cents per share, excluding a non-cash expense related to the company’s collaboration with CytomX. The company’s loss was at par with the Zacks Consensus Estimate but wider than the year-ago loss of 2 cents per share. ImmunoGen’s loss in the reported quarter was 44 cents including the non-cash expense. Results in the reported quarter were affected by lower revenues. ImmunoGen’s revenues in the third quarter fiscal 2014 declined 72.5% year over year to $6.9 million. The massive fall in revenues in the quarter was primarily due to a decrease in revenues from license and milestone fees. Revenues in the fiscal third quarter were also well below the Zacks Consensus Estimate of $13 million. ImmunoGen, Inc.(NASDAQ:IMGN) shares fell -3.65% in last trading session and ended the day on $11.09. ImmunoGen, Inc.(NASDAQ:IMGN) return on assets is -14.50%. ImmunoGen, Inc.(NASDAQ:IMGN) quarterly performance is -22.61%.
An investor who currently holds shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) filed a lawsuit against the CEO of AVEO Pharmaceuticals, Inc. and seven other officers over alleged breaches of fiduciary duties in connection with AVEO Pharmaceuticals’ drug Tivopath or tivozanib. AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO) shares moved down-4.35 % in last trading session and was closed at $1.10, while trading in range of $1.09 – 1.24. AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO) year to date (YTD) performance is -39.89%.
Genetic Technologies Limited (NASDAQ: GENE) announced it has filed its Quarterly Activities Report for the Quarter ended March 31, 2014 in accordance with the ASX. Total cash receipts from customers during the quarter ended March 31, 2014 were $1.4 million taking the equivalent figure to more than $3.7 million for the nine-month period ended on that date.Domestic testing revenues for the quarter under review continue to exceed budget expectations and the revenue received for the Company’s flagship test BREVAGen™ in the March quarter grew more than 39% over the preceding December quarter. As reported in the Company’s 2013 Annual Report, the revenues generated from the sale of the BREVAGen test are still recorded on a cash, not an accruals, basis. The Company anticipates that this treatment will change at the end of the 2014 financial year, with an appropriate upward adjustment to revenues being made at that time. Genetic Technologies Limited (ADR)(NASDAQ:GENE) ended the last trading day at $1.06. Company weekly volatility is calculated as 7.88% and price to cash ratio as 14.93. Genetic Technologies Limited (ADR)(NASDAQ:GENE) showed a negative weekly performance of -22.06%.